Document is current
Any future updates will be listed below
-
Authors
Hirayama, Masaya
Ohyama, Yukako
Tsuji, Yudai
Enomoto, Tetsuro
Hasegawa, Midori
Tsuboi, Naotake
Novak, Jan
Takahashi, Kazuo https://orcid.org/0000-0002-5774-4620
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science London (20K22915, 22K16230, 22K08366)
Aichi Kidney Foundation
Foundation for the National Institutes of Health (DK078244, DK082753)
UAB research-acceleration funds (AI149431)
- License Information
-
More Information
Article History
Received: 14 May 2024
Accepted: 7 March 2025
First Online: 7 April 2025
Declarations
:
: JN is a co-inventor on US patent application 14/318,082 (assigned to the UAB Research Foundation) and a co-founder, co-owner, and consultant for Reliant Glycosciences, LLC, and received honoraria from Travere, Inc, Calliditas, and Vera Therapeutics. NT received honorarium from AstraZeneca K. K. and Kissei Pharmaceutical Co., Ltd.; research funds from Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanofi Co., Ltd., and Zenyaku Holdings Co., Ltd.; donations from Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., and Torii Pharmaceutical Co., Ltd.; and travel fee from Sanofi Co., Ltd. The other authors declare no competing interests.
: All experimental protocols were approved by the Institutional Review Board (IRB) of Fujita Health University (approval number: HM22-140). Informed consent was obtained from all participants. All experimental methods were performed in accordance with the relevant guidelines and regulations.
